Merck is bucking the trend of its biopharma peers by continuing to invest in and build its infectious disease pipeline. With new regulatory pathways in play and novel funding mechanisms for antibiotics starting to take off, the pharma believes its decision to stay the course will be rewarded.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,